Research programme: biodefence vaccines and therapeutics - Ligocyte Pharmaceuticals

Drug Profile

Research programme: biodefence vaccines and therapeutics - Ligocyte Pharmaceuticals

Alternative Names: Anthrax vaccines - LigoCyte Pharmaceuticals; Biodefense vaccines and therapeutics - Ligocyte Pharmaceuticals; Intranasal, dry powder anthrax vaccine - LigoCyte Pharmaceuticals; MC-D12; MC-D13; MC-L31; Mucosal anthrax vaccine - LigoCyte Pharmaceuticals

Latest Information Update: 13 Oct 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator LigoCyte Pharmaceuticals
  • Developer Takeda
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Anthrax

Most Recent Events

  • 05 Oct 2012 LigoCyte Pharmaceuticals has been acquired and merged into Takeda
  • 28 Nov 2007 This programme is still in active development
  • 25 Jul 2003 Preclinical trials in Anthrax in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top